Traders should monitor Enbumyst's commercial ramp-up, future milestone achievements, and integration into Esperion’s sales infrastructure. The acquisition significantly expands Esperion’s addressable market and could drive re-rating if sales meet expectations. Watch for commentary on profitability and cash runway during the March 3 conference call.
ESPR drugs
ESPR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $2.91entry
- T+1 · 9mo ago 0.00%α −0.76% · $2.91
- T+5 · 8mo ago −7.22%α −6.74% · $2.70
- T+20 · 8mo ago −5.84%α −1.44% · $2.74
- T+60 · 6mo ago +7.56%α −2.76% · $3.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Esperion Therapeutics is acquiring Corstatis Therapeutics to gain full rights to Enbumyst™, the first FDA-approved nasal spray diuretic for edema associated with congestive heart failure, liver, and kidney disease. The deal includes a $75 million upfront cash payment, up to $180 million in potential milestone payments, and low double-digit royalties on future sales, with financing from existing credit facilities and royalty monetization. The acquisition expands Esperion’s cardiovascular portfolio and leverages its commercial infrastructure to target a U.S. market opportunity exceeding $4 billion.
Key Financial Metrics
Key Facts
- Esperion is acquiring Corstasis Therapeutics to add Enbumyst™ (bumetanide nasal spray) to its portfolio.
- Enbumyst is the first and only FDA-approved nasal spray loop diuretic, approved in September 2025 for edema in CHF, hepatic, and renal disease.
- Deal includes $75 million upfront cash payment, up to $180 million in milestone payments, and low double-digit royalties on global sales.
- Transaction expected to close in Q2 2026, financed through existing credit facilities and royalty monetization with Athyrium and HealthCare Royalty.
- Enbumyst targets a U.S. market opportunity exceeding $4 billion, with potential expansion into nephrotic syndrome and other indications.
- Acquisition aligns with Esperion’s Vision 2040 and complements its established cardiovascular commercial platform.
Financial Impact
$75 million upfront cash outlay, $180 million in potential milestone payments, and royalty obligations; expected to accelerate double-digit revenue growth
Risk Factors
- Failure to achieve anticipated commercial uptake of Enbumyst
- Integration risks and execution challenges in scaling a new product
- Potential dilution or increased leverage from financing structure
- Forward-looking statements may not materialize as expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248116 |
Track record
21 reports on ESPR
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers